The U.S. Food and Drug Administration (FDA) is the U.S. agency responsible for regulating foods, cosmetics, drugs, biologics, and blood derivatives; recently approved First vaccine for pregnant women prevent disease lower respiratory tract (ERTB) and severe ESRD caused by respiratory syncytial virus (RSV).
Per year, Respiratory syncytial virus hospitalizes nearly 50,000 children and infants worldwideAccording to the U.S. Centers for Disease Control and Prevention. RSV is often more severe in the winter, the illness lasts longer than usual and often leads to death if not treated properly.
Babies most likely to become infected with RSV are infants from birth to 6 months of age, so FDA approves vaccine developed by Pfizer lab called Abrysvo.
In many of the cases that have been presented, This virus is often confused with the common cold.Therefore, it is important to recognize these signs well. According to the World Health Organization, symptoms associated with this virus are:
- Runny nose, coughing, sneezing, fever, and wheezing (whistling sound when breathing)
- Loss of appetite
- irritability
- Less activity
- Difficulty breathing
What does the research show?
According to research conducted by the FDA, a baby’s immune system is weak in the first few months of life and relies on the mother’s protection; RSV vaccine protects baby before birthwhich gives the mother time to produce antibodies that circulate through the placenta to the fetus to fight the virus.
During the trial, approximately 3,500 pregnant women received the Abrysvo vaccine, while another group of 3,500 pregnant women received a placebo. The drug has been shown to reduce the risk of lower respiratory tract infections by 81.8% The increase was 69.4% within 90 days after delivery and 69.4% within 180 days after delivery.
Apart from, Another group of participants between 32 and 36 weeks gestation had a 34.7% reduction in risk; The risk of respiratory syncytial virus-related severe respiratory infection in the first 90 days of life was reduced by 91.1% compared to placebo.
In itself, Pharmaceutical company Pfizer mentioned the need to conduct relevant safety studies for its subsequent commercializationfollow the regulations of FNA.